Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)
Others
Ratios

Benitec Biopharma (BNTC) EBITDA (2019 - 2025)

Benitec Biopharma's EBITDA history spans 7 years, with the latest figure at -$9.4 million for Q1 2025.

  • For Q1 2025, EBITDA fell 125.42% year-over-year to -$9.4 million; the TTM value through Mar 2025 reached -$28.6 million, down 31.8%, while the annual FY2024 figure was -$21.8 million, 13.92% down from the prior year.
  • EBITDA for Q1 2025 was -$9.4 million at Benitec Biopharma, down from -$9.2 million in the prior quarter.
  • Across five years, EBITDA topped out at -$3.5 million in Q1 2022 and bottomed at -$9.4 million in Q1 2025.
  • The 5-year median for EBITDA is -$4.8 million (2021), against an average of -$5.3 million.
  • The largest annual shift saw EBITDA increased 12.6% in 2024 before it plummeted 125.42% in 2025.
  • A 5-year view of EBITDA shows it stood at -$4.9 million in 2021, then decreased by 14.21% to -$5.6 million in 2022, then decreased by 25.11% to -$7.0 million in 2023, then plummeted by 32.67% to -$9.2 million in 2024, then dropped by 1.46% to -$9.4 million in 2025.
  • Per Business Quant, the three most recent readings for BNTC's EBITDA are -$9.4 million (Q1 2025), -$9.2 million (Q4 2024), and -$5.2 million (Q3 2024).